EGFR and non-small cell lung carcinoma: Taking into account the positive OS results derived from the addition of chemotherapy to first-generation TKIs for the first-line treatment of patients with EGFR-mutated NSCLC,99 randomised trials exploring osimertinib combined with chemotherapy in the same clinical setting are needed.